Navigation Links
ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrig's Disease
Date:8/19/2008

Donated blood and tissue samples to be used to identify molecular signature of motor neuron disease

CAMBRIDGE, Mass., Aug. 19 /PRNewswire-USNewswire/ -- ALS Therapy Development Institute (ALS TDI) announced today the acceleration of an ALS biomarker effort using blood samples collected through an expanded network of clinical partnerships. These ongoing projects are part of the Institute's extensive effort to indentify the altered expression of genes and proteins, at the onset of, and throughout the progression of the fatal neurodegenerative disease known as amyotrophic lateral sclerosis (ALS, commonly known as Lou Gehrig's disease). The knowledge generated through this effort will be crucial to the identification of potential biomarkers which could be used for diagnosis and monitoring of disease progression, and will be useful for researchers worldwide in the effort to develop truly effective therapeutics. To facilitate additional ALS patient participation, ALS TDI has recently executed or submitted protocols to several additional hospitals and clinics for the collection of additional blood samples, as well as muscle and adipose tissue. The program is designed to include all ALS patients, regardless of whether they have a sporadic or inherited form of the disease.

"These types of ongoing projects, made possible only through collaborations with our clinical partners, are critical to determining the molecular signatures of this extremely complicated disease. The efforts of our clinical partners to carefully collect these biological samples, as well as the relevant clinical information from each patient, is central for the success of this project," said Steve Perrin, Ph.D., chief scientific officer of ALS TDI.

ALS is a neurodegenerative disease resulting in progressive paralysis and is considered fatal. The disease typically strikes without an identifiable cause, indiscriminately affecting a new family every 90 minutes in the U.S. That incidence rate is similar to that of multiple sclerosis, but the typical survival prognosis given to an ALS new patient is only 2-5 years from the date of diagnosis. Currently there is no known cure for ALS and only one FDA-approved drug, with marginal efficacy, for treating the disease.

The data analysis from this developing translational database has already begun and will be compared with the ALS TDI transcriptome database for the SOD1 mouse collected last year. To date, the Institute has cataloged and analyzed the world's largest collection of information on the molecular changes in the leading mouse model in the effort to establish the fundamental pathological mechanisms of this devastating disease. These ongoing projects are made possible as part of a major, three-year, $18 million funding and scientific collaboration with the Muscular Dystrophy Association (MDA) and its Augie's Quest Initiative, entered into at the beginning of 2007.

"We're pleased to be part of this project that gives our patients an opportunity to participate in very significant research. By collaborating with ALS TDI, a broad spectrum of people living with ALS are now involved in the creation of therapeutics," said Stanley Appel, M.D., co-founder & co-director of the Methodist Neurological Institute in Houston, Texas.

At the time of this announcement, ALS TDI had three clinical locations set up to collect blood donations and clinical information from ALS patients; Methodist Neurological Institute, University of California - Irvine, and Mount Sinai Medical Center. Mount Sinai has approved both blood and muscle tissue collection protocols. All three of these clinics are MDA/ALS Centers. ALS TDI plans to continue to accelerate its biomarker program and has submitted several additional protocols for review and approval to hospitals and clinics in other parts of the U.S. ALS patients and others interested in learning more are encouraged to contact, Beth Levine, Senior Associate Scientist and Project Manager, via email at blevine@als.net or by phone at (617) 441-7200.

About the ALS Therapy Development Institute

The ALS Therapy Development Institute (ALS TDI) (http://www.als.net), based in Cambridge, Mass., operates the world's largest research and development program focused exclusively on ALS. At ALS TDI, a staff of over 30 scientists and research technicians work on behalf of ALS patients to discover and advance novel therapeutics for treating, and ultimately curing, ALS. The nonprofit biotechnology institute excels in identifying novel disease targets, discovering compounds that may act against these targets, and screening potential treatments for clinical development.

About Augie's Quest

Fitness pioneer Augie Nieto started Augie's Quest (http://www.augiesquest.org) in conjunction with MDA's ALS Division. Nieto is co-founder and former president of Life Fitness of Chicago, and chairman of Octane Fitness. He and his wife, Lynne, serve as co-chairpersons of MDA's ALS Division. Nieto received a diagnosis of ALS in March 2005.

About MDA

MDA (http://www.mda.org) is the world's largest provider of ALS services and funder of ALS research. Over the years, it has expended $230 million in this effort. It operated 225 clinics across the county, 38 of which are ALS-specific research and care centers.

Media Contacts: Robert Goldstein, ALS TDI, 617.441.7295, rgoldstein@als.net


'/>"/>
SOURCE ALS Therapy Development Institute
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
2. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
3. Progesterone Therapy and Preterm Birth: More Evidence Helps Identify Women Who Can Benefit
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain
6. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
7. St. Jude Discovers Factors That Accelerate Resistance to Gleevec(TM) Targeted Therapy in Lymphoblastic Leukemia
8. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
9. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
10. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)...  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... it will be participating in the Deutsche Bank Securities ... in Boston, Massachusetts on Wednesday, ... a.m. Eastern Time. A live webcast of ... Relations website at http://investor.zimmerbiomet.com .  The webcast will ...
(Date:4/20/2017)... 2017  CVS Pharmacy, the retail division of ... store design to enhance the retail customer experience ... products and expanded beauty selections paired with informational ... new offerings. Together with its innovative digital programs, ... customer experience at CVS Pharmacy.  ...
(Date:4/20/2017)... -- Eyevensys, a private biotechnology company developing ... technology that enables the safe, local, sustained production of ... range of ophthalmic diseases, announces it has received approval ... (MHRA) to advance its technology into clinical development. ... The EyeCET platform ...
Breaking Medicine Technology:
(Date:4/21/2017)... ... 2017 , ... Brady (NYSE:BRC), a global leader in industrial and ... B-7569 vinyl label materials received certification for the BS5609 British Marine Standard. This ... and legible, for use on chemical drums shipped by sea. , “Achieving ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... Dudnyk has ... identity emphasizes the agency’s conviction that the full potential of specialty and orphan brands ... equally appreciated and aligned. , “The Unifying Effect is at the heart of ...
(Date:4/21/2017)... ... April 21, 2017 , ... The Patient Advocacy Community ... System, with the 2017 Ruth Ravich Patient Advocacy Award in recognition of ... DeVaro was honored with the award at The Beryl Institute’s annual Patient Experience ...
(Date:4/21/2017)... ... ... The Hong Kong Polytechnic University (PolyU) launched today the University Research Facility in ... Kong to support teaching, learning and research. It is also the largest research centre ... Kong. , With an area of 620 square metres and more than 50 ...
(Date:4/21/2017)... ... 2017 , ... The American Medical Student Association (AMSA) will ... Education, from April 24 to April 28, 2017, dedicated to increasing awareness about ... mission of AWARE is to instill a compassionate, total health approach to treating ...
Breaking Medicine News(10 mins):